Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9WVE

Crystal structure of HLA-A*11:01 in complex with KRAS G12A 10-mer peptide (VVVGAAGVGK)

Summary for 9WVE
Entry DOI10.2210/pdb9wve/pdb
DescriptorHLA class I histocompatibility antigen, A alpha chain, Beta-2-microglobulin, VAL-VAL-VAL-GLY-ALA-ALA-GLY-VAL-GLY-LYS, ... (4 entities in total)
Functional Keywordscomplex, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains12
Total formula weight188036.20
Authors
Jiali, Z.,Linlin, Z. (deposition date: 2025-09-19, release date: 2025-12-24, Last modification date: 2026-01-21)
Primary citationZhu, J.,Chen, Z.,Xu, X.,Wang, Y.,Liu, P.,Wen, M.,Wang, Q.,He, Y.,Jin, H.,Xue, H.,Wang, S.,Xu, K.,Zhao, L.
Structure guided analysis of KRAS G12 mutants in HLA-A*11:01 reveals a length encoded immunogenic advantage in G12D.
Commun Biol, 9:26-26, 2025
Cited by
PubMed Abstract: KRAS G12 mutations are frequent oncogenic drivers, yet their differential immunogenicity complicates T cell-based therapies. Here, we integrate structural, biophysical, and functional analyses to examine how KRAS G12 variants remodel peptide-MHC-I (pMHC) architecture and T cell receptor (TCR) recognition. Using HLA-A*11:01, we show that single residue substitutions at position 12 induce distinct conformational changes in the MHC groove, with G12D uniquely destabilizing the complex through a buried aspartate side chain. Notably, G12D peptides adopt two registers, a 9-mer and a 10-mer, that diverge sharply in structure and immunogenicity. The 10-mer forms a compact, stable pMHC with a TCR-accessible surface, while the 9-mer adopts a bent conformation incompatible with recognition. Molecular dynamics and NMR titration confirm the superior stability and binding affinity of the 10-mer. These results highlight how peptide length and conformation critically shape immune visibility, offering mechanistic insight for optimizing TCR-T therapies against elusive neoantigens like KRAS G12D.
PubMed: 41339521
DOI: 10.1038/s42003-025-09285-0
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

248636

PDB entries from 2026-02-04

PDB statisticsPDBj update infoContact PDBjnumon